APO-MONTELUKAST TABLET (CHEWABLE)
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
02-11-2021
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
MONTELUKAST (MONTELUKAST SODIUM)
Tilgjengelig fra:
APOTEX INC
ATC-kode:
R03DC03
INN (International Name):
MONTELUKAST
Dosering :
5MG
Legemiddelform:
TABLET (CHEWABLE)
Sammensetning:
MONTELUKAST (MONTELUKAST SODIUM) 5MG
Administreringsrute:
ORAL
Enheter i pakken:
15G/50G
Resept typen:
Prescription
Terapeutisk område:
LEUKOTRIENE MODIFIERS
Produkt oppsummering:
Active ingredient group (AIG) number: 0133823001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2019-04-26
Preparatomtale
Page 1 of 31
PRODUCT MONOGRAPH
PR
APO-MONTELUKAST
montelukast (as montelukast sodium)
4 mg and 5 mg chewable tablets
Leukotriene Receptor Antagonist
APOTEX INC.
DATE OF REVISION:
150 Signet Drive
November 2, 2021
Toronto, Ontario
M9L 1T9
SUBMISSION CONTROL NO.: 256160
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS........................................................................................................
7
DRUG INTERACTIONS
.......................................................................................................10
DOSAGE AND
ADMINISTRATION......................................................................................12
OVERDOSAGE
...................................................................................................................13
ACTION AND CLINICAL
PHARMACOLOGY.......................................................................13
STORAGE AND STABILITY
................................................................................................17
DOSAGE FORMS, COMPOSITION AND
PACKAGING..........................................................17
PART II: SCIENTIFIC
INFORMATION.................................................................................18
PHARMACEUTICAL INFORMATION
..................................................................................18
CLINICAL
TRIALS..............................................................................................................19
TOX
Les hele dokumentet
